Read More Pharma Industry News Pharming expands Joenja into children as rare-disease growth offsets RUCONEST pressure Pharming has secured FDA approval for Joenja in children aged four to 11 weighing at least 27 kg, widening a rare-disease franchise whose quarterly revenue grew 40% while RUCONEST declined. bySrinathSeptember 19, 2026